Literature DB >> 21073160

Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.

Luciana Auzzas1, Andreas Larsson, Riccardo Matera, Annamaria Baraldi, Benoît Deschênes-Simard, Giuseppe Giannini, Walter Cabri, Gianfranco Battistuzzi, Grazia Gallo, Andrea Ciacci, Loredana Vesci, Claudio Pisano, Stephen Hanessian.   

Abstract

Nonpeptidic chiral macrocycles were designed on the basis of an analogue of suberoylanilide hydroxamic acid (2) (SAHA, vorinostat) and evaluated against 11 histone deacetylase (HDAC) isoforms. The identification of critical amino acid residues highly conserved in the cap region of HDACs guided the design of the suberoyl-based macrocycles, which were expected to bear a maximum common substructure required to target the whole HDAC panel. A nanomolar HDAC inhibitory profile was observed for several compounds, which was comparable, if not superior, to that of 2. A promising cytotoxic activity was found for selected macrocycles against lung and colon cancer cell lines. Further elaboration of selected candidates led to compounds with an improved selectivity against HDAC6 over the other isozymes. Pair-fitting analysis was used to compare one of the best candidates with the natural tetrapeptide apicidin, in an effort to define a general pharmacophore that might be useful in the design of surrogates of peptidic macrocycles as potent and isoform-selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073160     DOI: 10.1021/jm101092u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

Authors:  Sun Ea Choi; Sujith V W Weerasinghe; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2011-08-12       Impact factor: 2.823

2.  Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.

Authors:  Tao Liang; Xuben Hou; Yi Zhou; Xinying Yang; Hao Fang
Journal:  ACS Med Chem Lett       Date:  2019-07-05       Impact factor: 4.345

Review 3.  Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.

Authors:  Berkley E Gryder; Quaovi H Sodji; Adegboyega K Oyelere
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

4.  Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.

Authors:  Priya Poonia; Monika Sharma; Prakash Jha; Madhu Chopra
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

Review 5.  Small molecule inhibitors of zinc-dependent histone deacetylases.

Authors:  Florence F Wagner; Michel Weїwer; Michael C Lewis; Edward B Holson
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

6.  The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.

Authors:  Sun Ea Choi; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2012-10-02       Impact factor: 2.823

7.  Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays.

Authors:  Zainab Noor; Noreen Afzal; Sajid Rashid
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

Review 8.  Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease.

Authors:  Zi-Ying Wang; Wen Qin; Fan Yi
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

9.  In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.

Authors:  Jean-Baptiste Garsi; Lorenzo Sernissi; Vito Vece; Stephen Hanessian; Alison N McCracken; Grigor Simitian; Aimee L Edinger
Journal:  Eur J Med Chem       Date:  2018-09-21       Impact factor: 6.514

Review 10.  HDAC6 and ovarian cancer.

Authors:  Joshua Haakenson; Xiaohong Zhang
Journal:  Int J Mol Sci       Date:  2013-05-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.